HELP apheresis in hypercholesterolemia and cardiovascular disease: efficacy and adverse events after 8,500 procedures
Tóm tắt
Low density lipoprotein (LDL-C) apheresis is a last treatment option for hypercholesterolemic patientsresistant to conservative lipid-lowering therapy. In a retrospective analysis of 8,533 heparin-induced extra-corporeal LDL precipitation apheresis treatments (HELP), we evaluated the efficacy of LDL reduction, the rate of adverse events, and the progression of atherosclerosis. Between July 1992 and April 2009, we performed 8,533 HELP apheresis therapies in patients with familial hypercholesterolemia (FH). Inclusion criteria were FH with insufficient lipidological status under optimal drug therapy and diet, and at least 50 HELP therapies. Left ventricular function and valvular status was checked prior to the first apheresis therapy and at the end of the individual HELP program. Blood samples were taken directly before and after each therapy. Blood count, electrolytes, total cholesterol, LDL–C, high density lipoprotein (HDL–C), triglycerides, lipoprotein (a) (Lp(a)), and fibrinogen were measured. Adverse events were documented weekly. We evaluated 27 patients (19 men) with FH (age 49.2 ± 12.5 years (range 10–67 years)). The number of HELP treatments once weekly was between 50 and 790 applications. Mean follow-up time was 7.0 ± 5.2 years (range 1.3–16.6 years). Prior to the individual apheresis program, 44.4% of the patients had a three vessel disease (VD; 25.9% two VD, 25.9% one VD) and 7.4% had a peripheral arterial occlusive disease. During the time of HELP treatment, none of the patients had a myocardial infarction; 3.7% had one percutaneous coronary intervention (PCI), 11.1% two PCI, 14.8% three PCI, 11.1% ³ four PCI. The patients received 1.2 ± 1.6 (range 0–5) PCI during follow-up time. Adverse events directly associated with HELP therapy were very rare (< 3%). Mean elimination of LDL-C was 63.49 ± 7.1%. The HELP apheresis therapy was well accepted by the patients in our programs. Adverse events during HELP apheresis were rare. This data is in line with the experiences published by other authors who reported an adverse event rate of 3.6% in adults. The LDL-HDL ratio, one of the strongest predictors of premature CHD events, improved significantly during the apheresis program. HELP is a safe, comfortable, and highly effective treatment in which adverse events are rare. It can reduce the burden of atherosclerosis, with no myocardial infarction and a low coronary intervention rate in our patients.
Từ khóa
Tài liệu tham khảo
Lloyd-Jones DM, Larson MG, Beiser A, Levy D (1999) Lifetime risk of developing coronary heart disease. Lancet 353:89–92
Krebs A, Krebs K, Keller F (2004) Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. Int J Artif Organs 27:137–148
Koga N (2001) Effects of low-density lipoprotein apheresis on coronary and carotid atherosclerosis and diabetic scleredema in patients with severe hypercholesterolemia. Ther Apher 5:244–251
Goldberg AC, Hopkins PN, Toth PP et al (2011) Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 5:S1–8
Klingel R, Mausfeld P, Fassbender C, Goehlen B (2004) Lipidfiltration—safe and effective methodology to perform lipid apheresis. Transfus Apher Sci 30:245–254
Bosch T, Wendler T (2004) State of the art of low-density lipoprotein apheresis in the year 2003. Ther Apher Dial 8:76–79
Schettler V, Jaeger BR, Klingel R (2009) The German lipid apheresis registry—remaining to be established. Atheroscler Suppl 10:59–61
Thompson GR (2010) Lipoprotein apheresis. Curr Opin Lipidol 21:487–491
Thompsen J, Thompson PD (2006) A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 189:31–38
Donner MG, Parhofer KG, Richter WO, Schwandt P (1999) Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism 48:881–886
Pulawski E, Mellwig KP, Horstkotte D (2003) H.E.L.P. apheresis and oxidative stress. Z Kardiol 92(Suppl 3):III38–41
Thompson GR, Barbir M, Davies D, Dobral P, Gesinde M, Livingston M, Mandry P, Marais AD, Matthews S, Neuwirth C, Pottle A, le Roux C, Scullard D, Tyler C, Watkins S (2010) Efficacy criteria and cholesterol targets for LDL apheresis. Athero sclerosis 208:317–321
Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, Paulweber B, Sijbrands E, Stalenhoef AF, Parhofer KG (2010) Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 21;492–498
Schuff-Werner P, Holdt B (2002) Selective hemapheresis, an effective new approach in the therapeutic management of disorders associated with rheological impairment: mode of action and possible clinical indications. Artif Organs 26:117–123
Hunt SA, Fuster V, Jacobs AK, Gibbons RJ, Russell RO (2003) American College of Cardiology; American Heart Association; American Society of Echocardiography. American College of Cardiology; American Heart Association; American Society of Echocardiography. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 108:1146–1162
Mellwig KP (2003) Heparin-induced extracorporeal low-density lipoprotein precipitation. Ther Apher Dial 7:365–369
Horstkotte D, Mellwig KP (2003) Heparin-induced extracorporeal LDL precipitation (H.E.L.P.). Z Kardiol 92(Suppl 3):III1–5
Jaeger BR (2001) Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis. Ther Apher 5:207–211
Mellwig KP, Baller D, Gleichmann U, Moll D, Betker S, Weise R, Notohamiprodjo G (1998) Improvement of coronary vasodilatation capacity through single LDL apheresis. Atherosclerosis 139:173–178
Mellwig KP, Baller D, Schmidt HK, van Buuren F, Wielepp JP, Burchert W, Horstkotte D (2003) Myocardial perfusion under H.E.L.P.–apheresis. Objectification by PET. Z Kardiol 92(Suppl 3):III30–7
Suckfuell M, Hearing Loss Study Group (2002) Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomised multicentre trial. Lancet 360:1811–1817
Kamimura M, Matsuo M, Miyahara T, Kimura K, Matsumoto K, Nakaya T, Abe T, Akizawa T (2002) Improvements in artery occlusion by low-density lipoprotein apheresis in a patient with peripheral arterial disease. Ther Apher 6:467–470
Kassner U, Vogt A, Rosada A, Barz F, Giannakidou-Jordan E, Berthold HK, Steinhagen-Thiessen E (2009) Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). Atheroscler Suppl 10:85–88
Gordon DJ, Knoke J, Probstfield JL, Superko R, Tyroler HA (1986) High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the lipid research clinics coronary primary prevention trial. Circulation 74:1217–1225
Moriarty PM, Gibson CA (2005) Association between hematological parameters and high-density lipoprotein cholesterol. Curr Opin Cardiol 4:318–323
Thompson GR (2008) Recommendations for the use of LDL apheresis. Atherosclerosis 198:247–255
Panagiotakos DB, Pitsavos C, Skoumas J, Chrysohoou C, Toutouza M, Stefanadis CI, Toutouzas PK (2003) Importance of LDL/HDL cholesterol ratio as a predictor for coronary heart disease events in patients with heterozygous familial hypercholesterolemia: a 15-year followup (1987–2002). Curr Med Res Opin 19:89–94
Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth DR, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stein EA, Stern TN, Troendle A, Zwiener RJ (1998) Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. Am J Cardiol 81:407–411
Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR (2008) Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 102:1199–1204